Show simple item record

dc.contributor.authorGudmundsdottir, E S
dc.contributor.authorJonsson, H
dc.date.accessioned2008-08-05T13:40:03Z
dc.date.available2008-08-05T13:40:03Z
dc.date.issued2000-10-01
dc.date.submitted2008-08-05
dc.identifier.citationScand. J. Rheumatol. 2000, 29(5):323-5en
dc.identifier.issn0300-9742
dc.identifier.pmid11093600
dc.identifier.urihttp://hdl.handle.net/2336/34253
dc.descriptionTo access publisher full text version of this article. Please click on the hyperlink in Additional Links fielden
dc.description.abstractIn this retrospective analysis of the DMARD CPH 82 in 44 Icelandic patients with severe refractory arthritis, clinical tolerance was good and serious side effects absent, although the majority were using the drug in combination with other DMARDS. Side effects leading to discontinuation were seen in 16% and the three year drug-survival was 51%.
dc.language.isoenen
dc.publisherTaylor & Francisen
dc.relation.urlhttp://search.ebscohost.com/login.aspx?direct=true&db=aph&AN=4103578&site=ehost-liveen
dc.subject.meshAdulten
dc.subject.meshAgeden
dc.subject.meshAnti-Inflammatory Agents, Non-Steroidalen
dc.subject.meshAntirheumatic Agentsen
dc.subject.meshArthritis, Rheumatoiden
dc.subject.meshDrug Therapy, Combinationen
dc.subject.meshFemaleen
dc.subject.meshGlycosidesen
dc.subject.meshHumansen
dc.subject.meshLignansen
dc.subject.meshMaleen
dc.subject.meshMiddle Ageden
dc.subject.meshRetrospective Studiesen
dc.subject.meshTime Factorsen
dc.subject.meshTreatment Failureen
dc.subject.meshTreatment Outcomeen
dc.titleCPH 82 (Reumacon) in refractory inflammatory arthritis.en
dc.typeArticleen
dc.contributor.departmentLandspitalinn University Hospital, Reykjavik, Icelanden
dc.identifier.journalScandinavian journal of rheumatologyen
html.description.abstractIn this retrospective analysis of the DMARD CPH 82 in 44 Icelandic patients with severe refractory arthritis, clinical tolerance was good and serious side effects absent, although the majority were using the drug in combination with other DMARDS. Side effects leading to discontinuation were seen in 16% and the three year drug-survival was 51%.


This item appears in the following Collection(s)

Show simple item record